$OTLK After FDA Approval: The Warrant–ATM–Reverse Split Spiral Retail Cannot Fight on Equal Terms

Executive summary

The post-approval collapse cannot be understood only as a conventional sell the news reaction. The market is reassessing a much larger issue: how a cash-constrained micro-cap can finance manufacturing, inventory, reimbursement infrastructure and a U.S. commercial launch while a large volume of warrants is available for exercise and resale.

The last verified public count was 186,996,998 shares outstanding as of June 22, 2026. The company subsequently completed an increase in authorized common stock from 260 million to 600 million shares. As of May 26, filings identified 71,366,978 shares issuable through outstanding warrants, plus 7,746,951 shares potentially issuable through conversion of a March 2025 note, and up to $100 million of common stock still available under an at-the-market equity program at that date.

A particularly important group of low-strike instruments became exercisable after shareholder approval and the increase in authorized shares. A July resale registration covered 17,258,065 warrant shares: 16,129,033 underlying private-placement warrants at $0.31 and 1,129,032 underlying placement-agent warrants at $0.3875. Separate previously issued warrants covering 2,142,854 shares had also been repriced to $0.31, while another 1,129,032 placement-agent warrants could become issuable upon exercise of the principal private-placement warrants.

The filings explicitly contemplate open-market sales, block trades, privately negotiated transactions, options and other hedging transactions. The securities purchase agreement also states that purchasers were not required to hold the securities for a specified period, could transact long or short after public disclosure, and could engage in hedging that might reduce the value of existing shareholders’ equity interests. These clauses are not proof that shorting or hedging occurred. They establish that the economic flexibility existed and that the company acknowledged its potential impact.

Why approval did not end the risk

FDA approval materially improves the value and strategic relevance of LYTENAVA. It does not automatically fund the commercial organization needed to convert that approval into durable revenue. A launch requires working capital, manufactured inventory, distribution, market access, reimbursement support, physician education and the ability to absorb a period in which expenses rise before sales become meaningful.

The company had already warned that its cash and cash equivalents at March 31, together with the gross proceeds from the April financing, were not sufficient to fund operations for one year from the filing date. It identified additional equity, debt, licensing, collaboration arrangements, regional rights and future product revenue as possible funding sources. SEC 10-Q

This produces a fundamental separation between asset value and common-equity value per share. The approved product can become more valuable while the common stock performs poorly if the capital required to monetize that product is raised through a rapidly expanding share count.

The share count was already expanding at exceptional speed

Four separate official reference points show how quickly the common-stock base changed before the FDA decision. The filings do not yet provide a complete transaction-by-transaction reconciliation for every share issued during this period, so the increase cannot be attributed exclusively to the ATM, warrant exercises, debt conversion or any single financing mechanism. The growth itself, however, is documented.

The exact warrant and financing structure

The most important accounting discipline is to avoid mixing outstanding shares with shares that may become outstanding. The 17.258 million shares covered by the July resale registration were issuable upon exercise. They should not be added to the 186.997 million current count unless a later filing confirms that the corresponding warrants were exercised.

The low-strike package that became economically powerful

The April transaction sold 16,129,033 common shares and issued an equal number of private-placement warrants. The combined purchase price was $0.31 per share plus accompanying warrant. The initial equity sale generated approximately $5 million gross. The warrants could generate another approximately $5 million if exercised in full for cash.

The same financing also produced 1,129,032 placement-agent warrants with a $0.3875 exercise price. Separately, 2,142,854 previously issued warrants were amended so that their strike fell from $2.26 to $0.31. Shareholder approval also contemplated another 1,129,032 placement-agent warrants that could become issuable upon exercise of the principal private-placement warrants.

What the resale registration actually permits

The registration statement does not say that all warrant shares have already been exercised or sold. It says that the selling holders may sell all, some or none of the covered shares. It registers the maximum number that could be resold after exercise and explains the permitted methods of distribution.

Those methods include ordinary brokerage transactions, block trades, purchases and resale by broker-dealers acting as principal, exchange distributions, privately negotiated transactions, arrangements to sell specified quantities at stipulated prices, and the writing or settlement of options or other hedging transactions. Shares may also be sold through a combination of those methods or through another lawful method. SEC resale filing

The registration statement also requires the company to use commercially reasonable efforts to keep the resale prospectus effective until the covered shares can be resold freely under an exemption or all covered warrant shares have been sold. This is not unusual in a private-placement financing, but it demonstrates how central resale liquidity was to the transaction.

Short sales and hedging: what the contract says

The securities purchase agreement is unusually direct about the purchasers’ trading flexibility. The company acknowledged that the purchasers had not been asked to stop buying or selling the company’s securities, long or short, or derivatives based on those securities, and had not agreed to hold the securities for any specified term.

The agreement also acknowledged that past or future open-market transactions—including short sales and derivatives—could negatively affect the public market price, that purchasers or their derivative counterparties might already have short exposure, and that one or more purchasers could engage in hedging while the securities remained outstanding. The company expressly recognized that such hedging could reduce the value of existing shareholders’ equity interests and would not, by itself, breach the transaction documents. SEC purchase agreement

The purchasers were prohibited from executing purchases or sales between execution of the agreement and the first public announcement of the transaction. After the announcement, the agreement did not impose a continuing contractual prohibition on securities transactions conducted in accordance with applicable law.

These clauses do not indicate that any prohibited trading activity occurred. They simply preserve broad trading and hedging flexibility, subject to Regulation SHO, Regulation M and other applicable securities laws. Public filings currently do not provide the transaction-level evidence required to determine how extensively those tools were used in OTLK.

Why the beneficial-ownership blocker does not eliminate selling pressure

The warrants generally include a beneficial-ownership limit of 4.99% or 9.99%, depending on the holder and its election. That limit restricts an exercise that would cause the holder’s beneficial ownership to exceed the applicable threshold immediately after issuance.

The blocker does not necessarily impose a permanent lifetime ceiling on the total number of warrant shares that may be monetized. A holder can potentially exercise a tranche, sell or otherwise dispose of shares, fall back below the ownership threshold and later exercise another tranche. The precise timing and legality depend on the warrant terms, beneficial-ownership calculations and applicable securities laws.

This is one reason the public outstanding-share count matters so much. A resale registration may reveal the maximum potential supply, but only a subsequent filing can confirm how many shares were actually issued through exercise.

The financing spiral can emerge through ordinary market mechanics

No common plan is required for this mechanism to develop. One investor may hedge, another may sell shares, the company may use its ATM and retail holders may reduce exposure independently. When these actions occur in the same period, their combined effect can become sustained downward pressure because each step reinforces the next.

The central economic problem is reflexivity: the lower the stock price, the more shares the company must issue to raise a fixed amount of money; the more shares the market expects, the less attractive each existing share becomes; and the weaker the price becomes, the greater the probability of a reverse split and another discounted transaction.

How the reverse split fits into the structure

Shareholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50, with the exact ratio left to the board. The authorized common-share count must be reduced proportionally when the reverse split is implemented. This is an important protection against the mistaken assumption that the company would retain 600 million authorized shares after consolidating the outstanding stock.

A reverse split does not create business value, cancel dilution or improve the company’s cash position. It changes the number of shares and the nominal price per share. Warrants, options and other equity-linked instruments receive proportional adjustments to share quantities and exercise prices.

The reverse split can still be strategically important even with proportional reduction of authorized shares. It can lift the nominal bid above $1, support Nasdaq compliance, move the stock out of sub-dollar territory and create a cleaner-looking numerical base from which another equity financing can be marketed.

Consider a purely illustrative 1-for-20 reverse split. A pre-split price of $0.50 becomes a theoretical $10. If the stock subsequently falls and a new financing is priced at $5 with additional warrants, the new financing price is economically equivalent to $0.25 on the pre-split basis. The headline offering price appears higher, but the effective entry valuation is lower.

Possible scenarios and editorial probabilities

The following percentages are Merlintrader editorial scenario weights, not mathematically derived probabilities, price targets or allegations. They reflect the financing documents, the verified share-count expansion, the low-strike warrant structure, the commercial funding requirement and the possibility that a strategic solution changes the path.

Scenario 1 — Progressive monetization and hedging: 40%

This is the most straightforward outcome. Financial purchasers exercise low-strike warrants progressively, sell shares, deliver them against hedges or retain some optionality. The company may use the ATM in parallel. The resulting pressure can arise from ordinary portfolio management and financing decisions, without any participant seeking a particular market outcome.

The likely result is persistent supply, a higher outstanding count, weak rallies and a market that refuses to capitalize the full commercial opportunity until the warrant and ATM overhang becomes quantifiable.

Scenario 2 — Reverse split and a new discounted raise: 35%

If the stock remains below the Nasdaq minimum bid level and launch funding remains inadequate, the board can implement the already-approved reverse split. A new registered direct offering, public offering, private placement, convertible instrument or stock-plus-warrant package could follow.

Existing financing participants have no automatic public right to receive the next transaction, but specialized capital frequently returns when a small company needs rapid funding. A lower adjusted valuation, new warrants and a reduced retail base may create more attractive terms for new professional capital than existed before approval.

Scenario 3 — Strategic solution interrupts the spiral: 20%

A credible partner, regional licensing transaction, commercial alliance, non-dilutive payment or early reimbursement and order data could materially improve the company’s negotiating position. Better capital quality would reduce reliance on the ATM, allow warrant supply to be absorbed and potentially limit the need for a punitive post-split raise.

This is the constructive scenario for existing shareholders, but it requires concrete evidence—not merely the regulatory approval itself.

Scenario 4 — Distressed recapitalization: 5%

The approved product makes a complete collapse less likely than it was before the FDA decision, but approval does not eliminate insolvency or listing risk. If financing closes, the price remains weak and commercial infrastructure cannot be funded, the company could accept extremely dilutive terms, renegotiate debt or face another severe compliance problem.

Why the structure is profoundly asymmetric for retail

The central issue is the structural asymmetry between professional financing participants and ordinary shareholders. They do not enter the transaction with the same instruments, protections or ability to manage risk.

This process can progressively reduce retail participation even when no participant is seeking that result. The professional side can monetize volatility, recycle capital and potentially negotiate a new position later. The retail side bears the direct mark-to-market loss and may exit before the underlying asset reaches commercial maturity.

The FDA catalyst can become the liquidity event through which instruments issued during the company’s period of maximum weakness are monetized. The shareholders who endured the regulatory risk do not necessarily receive the full economic benefit of regulatory success.

What is established, what is plausible and what remains unproven

What must be monitored next

The next filings should determine whether the current thesis is merely a risk scenario or an active recapitalization process. The most important evidence will not come from social-media theories. It will come from changes in issued shares, cash proceeds and instrument balances.

Bottom line

LYTENAVA’s approval is a genuine regulatory achievement and creates a real commercial asset. It does not guarantee a favorable outcome for the current common-share base.

The verified filings describe a company whose common shares had already expanded by approximately 54.7% in little more than a month, with 71.367 million warrant shares outstanding at May 26, a 17.258 million-share resale registration linked to very low strike prices, a convertible note capable of producing another 7.747 million shares, a $100 million ATM and authority to increase common stock to 600 million shares and execute a reverse split between 1-for-10 and 1-for-50.

The same contracts preserve broad trading flexibility for professional purchasers and explicitly recognize that short sales, derivatives and hedging may negatively affect the stock price and reduce the value of existing shareholders’ interests. That disclosure does not indicate misconduct. It shows that the transaction documents preserve professional risk-management and resale flexibility.

The most probable adverse path is an economically reflexive cycle in which warrant monetization, hedging, ATM sales, declining prices and dilution expectations reinforce one another until a reverse split or another financing resets the capital structure. This outcome can emerge from the interaction of the instruments and the company’s funding needs without requiring intentional price suppression.

For retail shareholders, the danger is profound because they lack the negotiated protections, instruments and flexibility available to professional financing participants. The approved product can succeed while the original common shareholders still experience severe destruction of value per share.